Pendulum company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Series C | Alive

Total Raised


Last Raised

$54M | 1 yr ago

About Pendulum

Pendulum Therapeutics is an evidence-based microbiome company that develops medical probiotics that target specific health conditions and provide the body the ability to naturally restore and improve one's health. The company offers a proprietary microbiome discovery platform and development approach that are enabling the identification of underlying microbiome mechanisms of action. This allows the company to develop a range of microbiome interventions for a variety of conditions, starting with metabolic diseases, to help improve patient health and wellbeing.

Pendulum Headquarter Location

933 20th Street

San Francisco, California, 94107,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Pendulum

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Pendulum in 1 CB Insights research brief, most recently on Sep 12, 2019.

Expert Collections containing Pendulum

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Pendulum is included in 5 Expert Collections, including Omics.



275 items


Artificial Intelligence

8,693 items

This collection includes startups selling AI SaaS, using AI algorithms to develop their core products, and those developing hardware to support AI workloads.


Game Changers 2018

36 items

Our selected startups are high-momentum companies pioneering technology with the potential to transform society and economies for the better.


Digital Health

12,788 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)


Biopharma Tech

838 items

Pendulum Patents

Pendulum has filed 19 patents.

The 3 most popular patent topics include:

  • Microbiology
  • Bacteriology
  • Microbiomes
patents chart

Application Date

Grant Date


Related Topics




Autosomal recessive disorders, Rare diseases, Microbiology, Bacteriology, Glucocorticoids


Application Date


Grant Date



Related Topics

Autosomal recessive disorders, Rare diseases, Microbiology, Bacteriology, Glucocorticoids



Latest Pendulum News

Pendulum Therapeutics Provides Leadership in Microbiome Education among Healthcare Professionals

Oct 28, 2021

Advancing Emerging Research May Transform Dietary Management of Type 2 Diabetes News provided by Share this article Share this article SAN FRANCISCO, Oct. 28, 2021 /PRNewswire/ -- Pendulum Therapeutics, a trailblazer in microbiome science and a pioneer in DNA sequencing, is leading healthcare professional education on the microbiome and its relationship to metabolic disease, including (among others) type 2 diabetes. Pendulum is arming healthcare professionals with new and emerging diabetes management research. Pendulum Glucose Control, a first-of-its-kind formulation of bothprobiotics and a prebiotic, is changing dietary management of type2 diabetes. Diabetes educators can join a free, online educational event on the microbiome on Nov. 2. Aimed primarily at diabetes educators, an upcoming online learning event (November 2, 2021) is one of many in a series this year that is advancing the scientific research on the microbiome and metabolic disease. To date, more than 1,200 professionals have registered for the upcoming event, a testament to the widespread interest in this emerging research. "Increasing diabetes educators' knowledge of the microbiome's role in gut health and diabetes management will help expand dietary options for people with type 2 diabetes," said Orville Kolterman, MD, chief medical officer, Pendulum Therapeutics. "Our research shows that the connection between the microbiome and disease is not well-understood among diabetes educators," Kolterman continued. "With hundreds of registrants for the educational events hosted by Pendulum to date – and more than a thousand registered for our event next week, it is clear that educators and clinicians are hungry for evidence-based, scientific research that will help improve patient care. "  Over the years, a growing body of evidence has linked unhealthy changes in the gut to increased risk for disease. More recently, peer-reviewed, published research  suggests that restoring the body's natural functionalities that appear compromised may enhance dietary management of metabolic disease, including type 2 diabetes. This novel restorative approach to dietary management of type 2 diabetes is so compelling, it was featured at the American Diabetes Association's (ADA's) 81st Scientific Sessions  earlier this year. The November session is one of a series of educational events sponsored by Pendulum Therapeutics. "At Pendulum, we are firmly committed to replicating the power of naturally occurring bacteria to improve overall health," said Colleen Cutcliffe, chief executive officer at Pendulum Therapeutics. "We do this using a proprietary method of DNA sequencing technology to develop novel formulations of bacterial strains that target specific deficits in the microbiome associated with metabolic dysfunction. Our first focus was type 2 diabetes, but the potential applications for this technology are extraordinary." Those interested can register  for the November 2nd event at . For more information or to purchase Pendulum Glucose Control, please visit . About Pendulum Therapeutics Pendulum Therapeutics believes therapies developed using evidence-based microbiome science and DNA sequencing can help heal the body from within. Armed with 14 patents and 46 pending, the company introduced its flagship product Pendulum Glucose Control , a medical probiotic, in 2020 and demonstrated its efficacy in lowering blood sugar spikes and reducing A1C in a published clinical trial . Founded in 2013 by a diverse team of scientists with deep microbiology, biochemistry, computational, and clinical expertise, Pendulum has raised $111 million to date from Meritech Capital, Sequoia Capital, True Ventures, Khosla Ventures, AME Cloud Ventures and Mayo Clinic among others. Pendulum Therapeutics is headquartered in San Francisco. Contact: Maureen Varnon

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.